BREAKING NEWS–Sandoz launches biosimilar product Zarxio in the U.S.

Following the end of the injunction imposed by the Federal Circuit’s July 21st opinion in Amgen v. Sandoz, Sandoz today launched its biosimilar product Zarxio–the first product to be approved under the BPCIA’s abbreviated approval pathway for biosimilars.  Zarxio is a biosimilar product referencing Amgen’s Neupogen (filgrastim) product, and will be sold at a 15% discount to Neupogen.

For more on what this means for the biosimilar world going forward, check back here on the Big Molecule Watch–we’ll be posting further analysis soon.